A Phase I Study of High-dose Pyrazoloacridine (PZA) (NSC 366140) Supported With Autologous Hematopoietic Stem Cell Rescue in Children With Recurrent or Resistant Neuroblastoma (IND # 36325)
Phase of Trial: Phase I
Latest Information Update: 07 Dec 2015
At a glance
- Drugs PD 115934 (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 08 Apr 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 29 Oct 2007 Status changed from suspended to completed.